RT Journal Article
SR Electronic
T1 Exploiting Homeostatic Repopulation to Increase DC Vaccine Efficacy in Multiple Myeloma
JF bioRxiv
FD Cold Spring Harbor Laboratory
SP 049072
DO 10.1101/049072
A1 Chandler D. Gatenbee
A1 Núria Folguera-Blasco
A1 Charlie Daneils
A1 Jill Gallaher
A1 Russ Rockne
A1 Casey Adams
A1 Michael Nicholson
A1 Eleni Maniati
A1 John Kennedy
A1 Kimberly Luddy
A1 Frederick L. Locke
A1 Mark Robertson-Tessi
YR 2016
UL http://biorxiv.org/content/early/2016/04/22/049072.abstract
AB Standard of care for multiple myeloma involves au-tologous hematopoietic cell transplant (AHCT), which can extend life by a year; however the disease remains incurable. A dendritic cell vaccine developed at Moffitt will be used both immediately before and after AHCT, with the aim of achieving complete response. Data will be collected during the trial to test the biological activity of the vaccine. This data will parameterize a model that facilitates the exploration of outcomes when varying the timing of vaccination. This calibrated model will also inform the design of a follow-up trial, which will include vaccination in conjunction with other immunotherapies.